Profile of veliparib and its potential in the treatment of solid tumors

References

• BasuBSandhuSKde BonoJSPARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancerDrugs201272121579159022834679
   PubMed Web of Science ®Google Scholar
• Olaparib approved for advanced ovarian cancerCancer Discov20155321825633525
   PubMed Web of Science ®Google Scholar
• DonawhoCKLuoYLuoYABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor modelsClin Cancer Res20071392728273717473206
   PubMed Web of Science ®Google Scholar
• KummarSKindersRGutierrezMEPhase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignanciesJ Clin Oncol200927162705271119364967
   PubMed Web of Science ®Google Scholar
• SalemAHGirandaVLMostafaNMPopulation pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignanciesClin Pharmacokinet201453547948824452810
   PubMed Web of Science ®Google Scholar
• LiXDelzerJVoormanRde MoraisSMLaoYDisposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly(ADP-ribose) polymeraseDrug Metab Dispos20113971161116921436403
   PubMed Web of Science ®Google Scholar
• PenningTDZhuGDGandhiVBDiscovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancerJ Med Chem200952251452319143569
   PubMed Web of Science ®Google Scholar
• LiJKimSShaXWiegandRWuJLoRussoPComplex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokineticsClin Cancer Res201420153931394424947923
   PubMed Web of Science ®Google Scholar
• KikuchiRLaoYBowDAPrediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K)J Pharm Sci2013102124426443224122511
   PubMed Web of Science ®Google Scholar
• McCabeNTurnerNCLordCJDeficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibitionCancer Res200666168109811516912188
   PubMed Web of Science ®Google Scholar
• LinFde GooijerMCRoigEMABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapyClin Cancer Res201420102703271324647572
   PubMed Web of Science ®Google Scholar
• DuanWGaoLAguilaBKalvalaAOttersonGAVillalona-CaleroMAFanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancerFront Oncol2014436825566506
   PubMedGoogle Scholar
• ShallSde MurciaGPoly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?Mutat Res2000460111510856830
   PubMed Web of Science ®Google Scholar
• MuraiJHuangSYDasBBTrapping of PARP1 and PARP2 by clinical PARP inhibitorsCancer Res2012722155885599
   PubMed Web of Science ®Google Scholar
• StewartEGoshornRBradleyCTargeting the DNA repair pathway in Ewing sarcomaCell Rep20149382984125437539
   PubMed Web of Science ®Google Scholar
• PalmaJPWangYCRodriguezLEABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumorsClin Cancer Res200915237277729019934293
   PubMed Web of Science ®Google Scholar
• PalmaJPRodriguezLEBontcheva-DiazVDThe PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivoAnticancer Res2008285A2625263519035287
   PubMed Web of Science ®Google Scholar
• GuptaSKMladekACCarlsonBLDiscordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus-resistant glioblastoma multiforme xenograftsClin Cancer Res201420143730374124838527
   PubMed Web of Science ®Google Scholar
• MuraiJZhangYMorrisJRationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibitionJ Pharmacol Exp Ther2014349340841624650937
   PubMed Web of Science ®Google Scholar
• SchaeferNGJamesEWahlRLPoly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphomaNucl Med Commun201132111046105121956491
   PubMed Web of Science ®Google Scholar
• NowsheenSBonnerJAYangESThe poly(ADP-ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapyRadiother Oncol201199333133821719137
   PubMed Web of Science ®Google Scholar
• EfimovaEVMauceriHJGoldenDWPoly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumorsCancer Res201070156277628220610628
   PubMed Web of Science ®Google Scholar
• AlbertJMCaoCKimKWInhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer modelsClin Cancer Res200713103033304217505006
   PubMed Web of Science ®Google Scholar
• LiuSKCoackleyCKrauseMJalaliFChanNBristowRGA novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxiaRadiother Oncol200888225826818456354
   PubMed Web of Science ®Google Scholar
• BarazzuolLJenaRBurnetNGEvaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastomaRadiat Oncol201386523510353
   PubMed Web of Science ®Google Scholar
• SheltonJWWaxweilerTVLandryJIn vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cellsInt J Radiat Oncol Biol Phys201386346947623540347
   PubMed Web of Science ®Google Scholar
• ShenYRehmanFLFengYBMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiencyClin Cancer Res201319185003501523881923
   PubMed Web of Science ®Google Scholar
• JelinicPLevineDANew insights into PARP inhibitors’ effect on cell cycle and homology-directed DNA damage repairMol Cancer Ther20141361645165424694947
   PubMed Web of Science ®Google Scholar
• PuhallaSBeumerJHPahujaSFinal results of a phase 1 syudy of single-agent veliparib in patient swith either BRCA1/2-mutated cancer, platinum-refractory ovarian, or basal-like breast cancer [Abstract 2570]J Clin Oncol2014325s
   PubMed Web of Science ®Google Scholar
• ColemanRLSillMWBell-McGuinnKA phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – An NRG Oncology/Gynecologic Oncology Group studyGynecol Oncol Epub 2015 Mar 24
   Web of Science ®Google Scholar
• LiuJFBarryWTBirrerMCombination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 studyLancet Oncol201415111207121425218906
   PubMed Web of Science ®Google Scholar
• KaufmanBShapira-FrommerRSchmutzlerRKOlaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutationJ Clin Oncol201533324425025366685
   PubMed Web of Science ®Google Scholar
• FongPCBossDSYapTAInhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriersN Engl J Med2009361212313419553641
   PubMed Web of Science ®Google Scholar
• RugoHSOlopadeODeMicheleAVeliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: first efficacy results from the I-SPY 2 trialCancer Res20137324 Suppl AbstractS502
   Google Scholar
• SomloGFrankelPHLuuTHPhase II trial of single-agent PARP inhibitor ABT-888 (veliparib) followed by post-progression therapy of veliparib with carboplatin in patients with BRCA-associated metastatic breast cancer [Abstract 1021]J Clin Oncol2014325s
   Web of Science ®Google Scholar
• KummarSOzaAMFlemingGFRandomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancerClin Cancer Res20152171574158225589624
   PubMed Web of Science ®Google Scholar
• KummarSJiJMorganRA phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomasClin Cancer Res20121861726173422307137
   PubMed Web of Science ®Google Scholar
• SuJMThompsonPAdesinaAA phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium reportNeuro Oncol201416121661166824908656
   PubMed Web of Science ®Google Scholar
• HussainMCarducciMASlovinSTargeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancerInvest New Drugs201432590491224764124
   PubMed Web of Science ®Google Scholar
• HeARTesfayeASmithDPhase II trial of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma [Abstract 240]J Clin Oncol2014323 Suppl
   Web of Science ®Google Scholar
• KunosCDengWDawsonDA phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group studyInt J Gynecol Cancer201525348449225594147
   PubMed Web of Science ®Google Scholar
• KummarSChenAJiJPhase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomasCancer Res201171175626563421795476
   PubMed Web of Science ®Google Scholar
• BrennerJCFengFYHanSPARP-1 inhibition as a targeted strategy to treat Ewing’s sarcomaCancer Res20127271608161322287547
   PubMed Web of Science ®Google Scholar
• ReissKAHermanJMZahurakMA phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosisClin Cancer Res2015211687625355929
   PubMed Web of Science ®Google Scholar
• MehtaMPWangDWangFVeliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 studyJ Neurooncol2015122240941725682091
   PubMed Web of Science ®Google Scholar
• EdwardsSLBroughRLordCJResistance to therapy caused by intragenic deletion in BRCA2Nature200845171821111111518264088
   PubMed Web of Science ®Google Scholar
• NorquistBWurzKAPennilCCSecondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomasJ Clin Oncol201129223008301521709188
   PubMed Web of Science ®Google Scholar
• BarberLJSandhuSChenLSecondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitorJ Pathol2013229342242923165508
   PubMed Web of Science ®Google Scholar
• JaspersJEKersbergenABoonULoss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumorsCancer Discov201331688123103855
   PubMed Web of Science ®Google Scholar
• RottenbergSJaspersJEKersbergenAHigh sensitivity of BRCA1-deificent mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsProc Natl Acad Sci U S A200810544170791708418971340
   PubMed Web of Science ®Google Scholar
• PettittSJRehmanFLBajramiIA genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicityPLoS One201384e6152023634208
   PubMed Web of Science ®Google Scholar
• GelmonKATischkowitzMMackayHOlaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyLancet Oncol201112985286121862407
   PubMed Web of Science ®Google Scholar
• LeeYHLiuXQiuFO’ConnorTRYenYAnnDKHP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapyPLoS One2015103e012120725769025
   PubMed Web of Science ®Google Scholar
• WangXWeaverDTThe ups and downs of DNA repair biomarkers for PARP inhibitor therapiesAm J Cancer Res20111330132721968427
   PubMed Web of Science ®Google Scholar
• MichelsJVitaleIGalluzziLCisplatin resistance associated with PARP hyperactivationCancer Res20137372271228023554447
   PubMed Web of Science ®Google Scholar
• FaraoniICompagnoneMLavorgnaSBRCA1, PARP1 and γH2AX in acute myeloid leukemia: role as biomarkers of response to the PARP inhibitor olaparibBiochim Biophys Acta20151852346247225483710
   PubMed Web of Science ®Google Scholar
• JacotWThezenasSSenalRBRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancerBMC Cancer20131352324191908
   PubMed Web of Science ®Google Scholar
• LiuJFKonstantinopoulosPAMatulonisUAPARP inhibitors in ovarian cancer: current status and future promiseGynecol Oncol2014133236236924607283
   PubMed Web of Science ®Google Scholar
• HortonTMJenkinsGPatiDPoly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activityMol Cancer Ther2009882232224219671751
   PubMed Web of Science ®Google Scholar